The PIVENS trial by Sanyal et al. [21] reassessed the associations between changes in alanine transaminase (ALT) levels in a group of subjects taking pioglitazone versus vitamin E versus Placebo in NASH. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.